The European Genomic Medicine Consortium (EGMEDC)

Accelerating the Clinical Translation of CRISPR and Genomic Medicines Across Europe

Who we are

The European Genomic Medicine Consortium (EGMEDC) is a pan-European, non-profit initiative established by CRISPR Medicine News (CMN) in collaboration with a founding group of leading European institutions, as well as partners and supporters from the biotech, pharmaceutical, and supplier sectors.

------

Mission

EGMEDC unites and empower clinical, academic, regulatory, and industry stakeholders to advance the development and delivery of CRISPR-based and related genetic therapies across Europe.

By aligning these efforts, the consortium aims to establish a coordinated, ethical, and sustainable ecosystem for the clinical translation of genomic medicines - ensuring timely, safe, and equitable access for patients.

------

Strategic Aims

The strategic priorities focus on solving Europe’s key translation bottlenecks.

  1. Clinical Coordination and Implementation:
    • Aligning cross-border trials, data sharing, and long-term monitoring.
  2. Infrastructure Mapping and Creation:
    • Connect Europe's fragmented screening, gene and cell therapy capabilities and implementing joint clinical-grade tools and protocols.
  3. Policy & Regulation:
    • Promote the harmonization of ethical frameworks, health technology assessment (HTA), and European Medicines Agency (EMA) regulatory pathways.
  4. Access & Reimbursement:
    • Support scalable and fair access models for genomic medicines across European states.
  5. Industry + Public Collaboration:
    • Bridging biotech, academic networks, national programs, and European initiatives to accelerate innovation and translation.

------

Membership

Membership opens in May 2026. To register your interest, please contact us.

------

Role of CMN

CMN is pleased to serve as one of the founding partners, supporting the dissemination of the consortium’s outputs to the community across Europe and globally.

 

EGMEDC

Stine Bosse, a Member of the European Parliament, delivered opening remarks at the #CRISPRMED26 conference in Copenhagen on April 13, 2026, officially launching EGMEDC. The launch in Copenhagen marked a milestone in accelerating clinical translation of CRISPR and genomic medicine across Europe, addressing rare disease treatment access.

EGMEDC
Founding Partners and Supporters

EGMEDC launched on April 13, 2026 and is now operationalising. Full secretariat activities commence in May 2026.

The following organisations and companies have confirmed their support for the initiative and their intention to contribute to its emerging structure. Their roles reflect areas of alignment and strategic interest and will be further defined during the formalisation of the consortium. This list will be updated on a monthly basis.

Membership opens in May 2026. To register your interest, please contact us.

Executive Board
  • Jens-Ole Bock (Chair), Founder, CMN, Denmark.
  • Cecilia Jimenez Mallebrera (Co-chair), PhD, Research Director, Neuromuscular Unit, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu Barcelona, Spain.
  • Alessia Cavazza, Ass. Prof. and Group leader, Zayed Centre for Research into Rare Diseases in Children, UCL Great Ormond Street Institute of Child Health, University College London, UK.
  • Ellen Koekoeckx, Global Advisor for the Foundation for Angelman Syndrome Therapeutics (FAST), Belgium.
  • Emmanuel Mussault, Founder of OHIO, Executive Board Members of the French Institute of Precision Medicine in Oncology, IHU PRISM, France
  • Özcan Met, PhD, Ass. Prof. and Head of Cell Therapy Unit and DTU HealthTech, CCIT-DK / DTU, Denmark.
Advisory Board
  • Pascale Berthet, Cell'Ectiv Consulting, France
  • Dr. Sam Ringle, Regulatory Affairs Consultant, Germany

EGMEDC now has its own bank account (IBAN: DK7873120001114547 / SWIFT: JYBADKKK) with Jyske Bank

The European Genomic Medicine Consortium (EGMEDC) is a voluntary, non-profit association registered in Denmark on 2026-02-10, CVR: 46256026 | Kalvebod Brygge 39, 5., 1560 Copenhagen V, Denmark | Jyske Bank, IBAN: DK7873120001114547 / SWIFT: JYBADKKK, secretariat@egmedc.eu | Articles of Association | Rules of Procedures of the Board | Rules of Procedures of the Secretariat | Board Meeting 2026-06-22_Minutes

Disclaimer

EGMEDC officially launched on April 13, 2026. Information on this website may be updated as the consortium continues to develop.

Copyright Notice

© 2026 European Genomic Medicine Consortium. All rights reserved.

EGMEDC
Seed Founding Supporters
Seed Founding Supporters
Seed Founding Supporters
Sponsors (gold)
Sponsors (gold)
close
Search CRISPR Medicine